



Session 2. New Concepts in Risk Stratification of Sudden Cardiac Death Sudden Death Risk in Patients with PVCs

Session 2. New Concepts in Risk Stratification of Sudden Cardiac Death

Sudden Death Risk in Patients with PVCs

Yoo Ri Kim MD., PhD. Dongguk University College of Medicine





Sudden Death Risk in Patients with PVCs

Possible cause of SCD in patients with PVC

- Malignant arrhythmogenic PVC itself \rightarrow fast VT to VF
- Benign PVC but malignant condition inherited arrhythmia syndrome
- Progressive PVC induced CMP (HF pump failure)
- Ischemic PVCs or DCMP





Focus to...

- Malignant PVC
 - PVC from conduction system (Purkinje system)
 - PVC from myocardium (outflow tract)
 - PVC on inherited arrhythmia syndrome
- PVC induced CMP (LV dysfunction \rightarrow HF, pump failure)
- Ischemic or DMCP PVC (arrhythmogenic substrate+)






VT Symposium 2021

Sudden Death Risk in Patients with PVCs

Mode of onset of malignant VA in iVF




J Cardiovasc Electrophysiol. 1997; 8:1115-1120.



VT Symposium 2021

Sudden Death Risk in Patients with PVCs

Short-coupled variant of TdP (RV fascicle)




Neth Heart J 2008;16:246-9.



VT Symposium 2021


Sudden Death Risk in Patients with PVCs





| | Sex, Female/Male | Age, y | Family History of Sudden Death | Number of VF Before Ablation | Episodic Arrhyth- mias | Monomorphic Premature Beats | Ectopic QRS Durations, ms | Coupling Interval Initiating VF or Polymorphic VT, ms |
|-----------------|---------------------|--------------------|-----------------------------------|---------------------------------|------------------------------|-----------------------------------|------------------------------|---|
| RVOT (n=4) | 3/1 | 27±8 | 0 | 2±2 | 4/0 | 1/3 | 145±12 | 355 ± 30 |
| Purkinje (n=23) | 11/12 | <mark>43±14</mark> | 6 | 10±13 | 4/19 | 18/5 | 126±18 | <mark>280±26</mark> |
| Р | NS | 0.02 | NS | 0.03 | <0.01 | 0.06 | 0.04 | 0.01 |


Circulation. 2002;106:962-967




VT Symposium 2021

Sudden Death Risk in Patients with PVCs

PVC originating from LV Purkinje system






Circulation. 2002;106:962-967



VT Symposium 2021

Sudden Death Risk in Patients with PVCs

PVC arising from the anterolateral PM






VT Symposium 2021

Sudden Death Risk in Patients with PVCs

PVC originating from moderator band



Heart Rhythm 2014;0:0-9



VT Symposium 2021

Sudden Death Risk in Patients with PVCs

Catheter ablation of VF triggers


| Authors | Year of publication | Number of patients | Aetiologies of VF | Ablation site | Follow-up duration | Outcome | |
|--------------------------------------|---------------------|---|---|---|--|---|---|
| Non-structura | l heart disease | | | | | | |
| Nademanee et al. ³⁶ | 2011 | 9 | Brugada syndrome | Areas of delayed depolarization over RVOT (anterior aspect) | 20 ± 6 months | No recurrent VF/VT in all patients off medication (except for one patient on amiodarone) | Number of patients In catheter ablation |
| Knecht et al. ⁴¹ | 2009 | 38 | Idiopathic VF | Targeted PVCs originating from Purkinje system | 63 months (median) | Seven patients (18%) experienced VF recurrence at median of 4 months. Five of these seven patients underwent repeat ablation without VF recurrence | for VF triggering PVC Outflow tract: 9+3 =12 mainly BrS or LQTs |
| Haissaguerre et al. ⁴⁰ | 2008 | 8 | Idiopathic VF (with early repolarization) | Purkinie tissue, ventricular myocardium or multiple sites | Specific follow-up of these patients not given | All PVCs eliminated in five patients; unsuccessful in three patients | Purkinje: 38+ 8+ 27 +16 = 56 |
| Haissaguerre et al. ⁴⁴ | 2003 | 7 (three with Brugada syndrome; four with LQTS) | Brugada syndrome and long QT syndrome | Targeted PVCs originating from Purkinje system (1 Brugada syndrome and three LQTS) or RVOT | 17 ± 17 months | No patient had recurrence of symptomatic ventricular arrhythmia but one had persistent PVC | |
| Haissaguerre et al. ³⁹ | 2002 | 27 | Idiopathic VF | Targeted Purkinje-like potentials originating from distal Purkinje system | 24 ± 28 months | Twenty-four patients (89%) had no recurrence of VF off medication | |
| Haissaguerre et al. ³⁸ | 2002 | 16 | Idiopathic VF | Earliest site of PVC activation at Purkinje system | 32 months | Successful in 13 patients—no VF recurrence or syncope | Tan VH. Europace 2012;14:1687-95 |




VT Symposium 2021

Sudden Death Risk in Patients with PVCs

PVC originating from RVOT







Sudden Death Risk in Patients with PVCs

PVC originating from RVOT





Table 1Comparison of ECG characteristics between malignantRVOT VT, benign RVOT VT, and idiopathic VF

| | Malignant RVOT VT | Benign RVOT VT | Idiopathic VF | Р |
|------------------------|----------------------|-------------------|------------------|--------|
| CI, ms: | | | | |
| Haissaguerre et al. | 355 ± 30 | _ | 280 ± 26 | .01 |
| Viskin et al. | 340 ± 30 | 427 ± 76 | 300 ± 40 | <.001 |
| Noda et al. | 409 ± 62 | 428 ± 65 | _ | .27 |
| QRS duration, ms: | | | | |
| Haissaguerre | 145 ± 12 | _ | 126 ± 18 | .04 |
| et al. | | | | |
| Noda et al. | 148 ± 8 | 142 ± 12 | | .03 |
| Cycle length of | | | | |
| VT, ms: | | | | |
| Noda et al. | 245 ± 28 | 328 ± 65 | — | <.0001 |


Heart Rhythm 2009;6:1507-1511



VT Symposium 2021

Sudden Death Risk in Patients with PVCs

Malignant vs. Benign OT PVC




J Cardiovasc Electrophysiol, 2012; 23:521-526



VT Symposium 2021

Sudden Death Risk in Patients with PVCs



Clinical outcomes of malignant OT VT

| Study | Case Presentation | | Procedure | Outcomes 24±28 months Free from VF in 24/27 (89%) Recurrent VF in 2, PMVT in 1 ¼ recurrent PVC in ROVT VT | |
|------------------------------|----------------------------------|-------------------------------------|--|---|--|
| Haïssagurre M. (Cir 2002) | 4/27 VF (3 F, 1M) | | 23/27 ICD, 4/27 early RFCA without ICD OT PVC – acutely elimination of 4~7 energy application | | |
| Viskin S. (JCE 2005) | Case 1 F/35 | Recurrent syncope | EPS – negative PACE map: anteroseptal of RVOT-> ICD | 8 years FU Free from VT without drug | |
| | Case 2 F/54 | Palpitation -> SCD | EPS – negative -> ICD | 2 years FU Free from VT without drug | |
| | Case 3 F/65 | Palpitation -> presyncope | EPS – NSVT induction RFCA : midseptal of RVOT | 5 months FU Free from VT | |
| Noda T. (JACC 2005) | 16 OTVT (9F, 7M) 39±10 | 11 Syncope 5 Presyncope 5 VF | 16/16 – induction (2 ISP, 1Epi, 1 ME) 3/16 Partial success -> BB 13/16 Success but 1 VF with PES->ICD 1 PMVT with PES -> BB | 54±39 months Free from VF, SCD in all 16 10 years FU 1 ARVD | |
| lgarashi M. (JCE 2012) | 18 PVT/VF (7M,38.9%) 43±14 | 11 Syncope 5 Presyncope 2 SCD | 17/18 EPS – no induction in 1 -> ICD 1/18 refused EPS -> ICD with BB | 63±19 months Free from syncope, SCD, VF <mark>2/17 recurrent PVC- redo</mark> | |
| Kurosaki K. (Cir J 2013) | 14 PVT (12F, 86%) 45±11 | 8 syncope 2 presyncope 4 VF | 13/14 (93%) – success 1/14 (7%) – partial success | 68±23 months Free from VT/VF No recurrent syncope or SCD | |
| Kim Y. (HR 2009) | 36 OTVT (18F, 50%) 43±16 | 36 Syncope 6 VF | 21/36 (62%) – success 7/36 (21%) – partial success <mark>6(17%) – failed</mark> | 48±35 months 1 SCD | |



Sudden Death Risk in Patients with PVCs

Long term outcome of RFCA for malignant OT PVC

EPS results (52 patients)

| Successful ablation of VT/PVC focus, n (%) | 37 (71.3) |
|--|--------------------------|
| Partial modification of VT/PVC focus, n (%) | 9 (17.0) |
| Failed induction or ablation, n (%) | 5 (10.6) |
| Single focus of VT/PVC, n (%) | 30 (65.2) |
| Acute complications of EP procedure, n (%) | 0 (0) |
| Long-term clinical outcomes (19/52 patients) | |
| Recurrent VT, n (%) | 5 (9.6) |
| Recurrent VF, n (%) | 9 (17.3) |
| Recurrent SCD, n (%) | 2 (3.8) |
| Redo ablation, n (%) | 3 (5.8) |
| Channelopathy(LQTs, BrS), ARVD, n (%) | 2 (4.0) |
| Antiarrhythmics, n(%) | 22 (42.3) |
| | YR Kim, presented at HRS |



Sudden Death Risk in Patients with PVCs

Long term outcome of RFCA for malignant OT PVC

| | Total (52) | No Recurrence (33) | Recurrence (19) | <i>P</i> Value |
|----------------------|------------|--------------------|--------------------|----------------|
| RFCA result | | | | |
| Success | 37 (71.2%) | 27 (73.0%) | 10 (27.0%) | 0.070 |
| Partial success | 9 (17.3%) | 4 (12.1%) | 5 (26.3%) | 0.070 |
| Fail or no induction | 6 (11.5%) | 2 (6.1%) | 4 (21.1%) | |
| Number of VT Foci | 1.39±0.58 | 1.35±0.55 | 1.47±0.64 | 0.543 |
| Complication | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 1.000 |
| Antiarrhythmics | 21 (42.0%) | 9 (26.5%) | 12 (75.0%) | 0.002* |
| ICD therapy | | | | |
| inappropriate | 1 | 1 (3.3%) | 0 (0.0%) | <0.001* |
| appropriate | 13 | 0 (0.0%) | 13 (68.4%) | |


YR Kim, presented at HRS 2017



VT Symposium 2021

Sudden Death Risk in Patients with PVCs

VT/VF free survival according to ablation success





Sudden Death Risk in Patients with PVCs

Possible mechanisms of malignant OT-VT

- Triggering activity secondary to cAMP-mediated DAD
- Intracellular Ca²⁺
 - Altered positive feedback of Ca²⁺ induced Ca²⁺ release.
 - Dispersion of refractoriness in ventricular myocardium by functional block or delayed conduction d/t rapid firing triggered activity
 - Up-regulation of the beta-adrenergic receptor system
 - Genetic mutation of RyR2

 \rightarrow Excessive release of SR Ca²⁺ by RyR2 phosphorylation

- Ventricular substrate
 - Alternation of QRS, more than one focus and lower success rate
 - Multiple myocardial foci or substrate-based micro-reentry
 - VT arising from the pulmonary artery








Session 2. New Concepts in Risk Stratification of Sudden Cardiac Death

Sudden Death Risk in Patients with PVCs

Spatial dispersion of APD







| Clinical Characteristics | Overall Sample $(n = 27)$ | Normal EVM Group A ($n = 20$) | Abnormal EVM Group B (n = 7) | p Value |
|---|---------------------------|------------------------------------|---------------------------------|---------|
| Age (yrs) | 33.9 ± 8 | 33.6 ± 6 | 34.1 ± 3 | 0.91 |
| Gender (male) | 15 (55) | 12 (60) | 3 (43) | 0.66 |
| Family history of sudden death | 3 (11) | 2 (10) | 1 (14) | 1.0 |
| Clinical symptoms | 25 (92) | 19 (88) | 6 (86) | 0.46 |
| Pre-syncope | 7 (26) | 4/19 (21) | 3/6 (50) | 0.30 |
| Palpitations | 18 (72) | 15/19 (79) | 3/6 (50) | 0.30 |
| Competitive athletes | 9 (33) | 7 (35) | 2 (28) | 1.0 |
| Interval between symptom onset and EVM (months) | 35 ± 8 | 35 ± 9 | 36 ± 4 | 0.9 |

rdiac Death with PVCs

Corrado D. JACC 2008;51:731-739


111



Session 2. New Concepts in Risk Stratification of Sudden Cardiac Death

Sudden Death Risk in Patients with PVCs

PVC initiated VF in LQTs and BrS



Circulation. 2003;108:925-928



VT Symposium 2021


Sudden Death Risk in Patients with PVCs

PVC initiated VF in ERS


B 6 a.m. 18 August 2003



C 10 a.m. 18 August 2003



D 10:46 a.m. 18 August 2003



Right precordial QT spatial dispersion >>


European Heart Journal (2010) 31, 330–339



Session 2. New Concepts in Risk Stratification of Sudden Cardiac Death


Sudden Death Risk in Patients with PVCs

Benign RVOT PVC trigger polymorphic VT in LQT 2



Clinical outcomes of malignant OT VT


- s/p ICD d/t VF-SCD 2016.7.20
- LQT epinephrine provocation (+)
- PVC couplet on T wave






Session 2. New Concepts in Risk Stratification of Sudden Cardiac Death

Sudden Death Risk in Patients with PVCs







Who's the enemy? What is the target?

• PVC itself?

- If monomorphic fast VT, yes!
- > If polymorphic VT, don't think so...but can be targeting to treatment

• PVC on the bad timing?

- short coupled PVC (1st CI) originating from Purkinge
- ➤ accelerated TCL (2nd CI) Outflow tract
- ➢ If presentation with SCD d/t VF ICD back up
- PVC with a latent inherited arrhythmia syndrome

continuous FU

If presentation with SCD d/t VF - ICD back up







Session 2. New Concepts in Risk Stratification of Sudden Cardiac Death Sudden Death Risk in Patients with PVCs

감사합니다

Thank you!

